← Back to all signals
RESEARCH PAPER ANALYSIS

Singing-Based Interventions for Treating Hypokinetic Dysarthria in Parkinson's Disease: A Systematic Review.

Systematic review of 23 mostly low-quality studies (381 participants) reporting that singing-based interventions—particularly those incorporating LSVT principles and group vocal exercises—can improve phonation, prosody, respiratory control and aspects of quality of life in people with Parkinson’s…

PMID41990042
JournalJournal of music therapy
Publication Date2026-02-11
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Systematic review of 23 mostly low-quality studies (381 participants) reporting that singing-based interventions—particularly those incorporating LSVT principles and group vocal exercises—can improve phonation, prosody, respiratory control and aspects of quality of life in people with Parkinson’s…

WHY IT MATTERS

Research significance

Provides moderate translational value as supportive, low-risk symptomatic therapy for PD-related hypokinetic dysarthria and guidance to combine singing with established voice therapy (LSVT), but offers little mechanistic or disease-modifying insight for therapeutic discovery.

ABSTRACT

Source abstract

Parkinson's disease (PD) progressively affects motor functions, often resulting in hypokinetic dysarthria, characterized by reduced speech articulation and vocal intensity. Over the last few decades, singing-based interventions have demonstrated potential therapeutic benefits for treating neurological speech disorders. To review the effectiveness of singing-based interventions in treating hypokinetic dysarthria, articles were identified based on a search across MEDLINE, PubMed, Scopus, ScienceDirect, and Web of Science. After being independently screened by the authors, the information was reviewed and extracted from articles written in English and Spanish investigating the potential benefits of music interventions in people living with PD. A total of 23 studies, out of 742 screened, involving 381 participants, were included. The majority of the studies were deemed of low quality due to the risk of bias from small sample sizes, lack of randomization, absence of control groups, and heterogeneous samples resulting from the progression of the disease. Overall, the review revealed that singing-based interventions improve phonation, prosody, and respiratory control, particularly those that incorporate group singing and vocal exercises based on speech-language pathology principles and techniques, such as the Lee Silverman voice treatment (LSVT). Findings suggest that singing-based interventions, when combined with and guided by LSVT principles, may maximize therapeutic benefits on speech quality in people living with PD. Additionally, several studies reported positive effects on emotional well-being and quality of life, reinforcing their potential psychosocial benefits. However, more studies with greater methodological rigor and long-term follow-up are needed to confirm these effects and establish more standardized intervention protocols.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic